Business Wire

VERIMATRIX

31.3.2022 17:47:08 CEST | Business Wire | Press release

Share
Verimatrix Threat Defense Empowers Capri Healthcare to Safely Digitize Doctor-Patient Care

Regulatory News:

Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Capri Healthcare chose Verimatrix App Shield , part of Verimatrix’s threat defense business line, to gain fast and proven defenses for its TriVice (triage, referral and advice) mobile app.

TriVice streamlines doctor-patient care by managing acute referrals to specialist clinicians routed through its mobile app. The app captures patient demographics, details of the injury/condition and facilitates the sharing of clinical photographs and images. The app triages and enables sending of Advise and Guidance with an aim to reduce avoidable referrals. Additionally, the app enables real-time notification and communication with referring clinicians as well as integration into existing hospital systems. TriVice makes the referral process easier, smoother, seamless and with better documentation. The app’s goal is to advance the digital-first strategy of the National Health Service (NHS), the publicly funded healthcare system in England.

An automated and self-defending cloud-based solution, Verimatrix App Shield provides Capri Healthcare with peace of mind that staff and patient experiences with its TriVice mobile app are protected against numerous nefarious activities. Though a zero-code (no programming required), SaaS approach, App Shield harden apps and helps prevent hacking attacks such as reverse engineering, application repackaging, dynamic modification, man-in-the-middle attacks and much more.

“Capri Healthcare is an organization driven by the vision of turning the NHS digital-first strategy into reality by bringing digital innovation into the working of healthcare providers,” said Krishna Thakur and Valleesh Athreya, founders at Capri Healthcare. “We are dedicated to using technology to improve care, identifying patient conditions earlier, reducing backlog, digitizing processes and eliminating wasteful tasks. We realize that all of that is only possible if we do so by deploying solutions that are secure and trusted by all. Verimatrix answers that need by quickly and cost-effectively adding enterprise-quality threat defense to our TriVice mobile app.”

“At Verimatrix, we are proud to support innovative organizations such as Capri Healthcare that develop, deploy and accelerate the adoption of breakthrough mobile health experiences that strive to make the world a healthier, better place,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “We are especially pleased to work with healthcare innovators like Capri Healthcare, as practitioners and patients alike see privacy and security as a standard expectation, especially as new digital processes are established and adopted. This announcement proves again that Verimatrix’s threat defense solutions are essential for the global healthcare market that is rapidly adopting mobile technologies.”

About Capri Healthcare
Capri Healthcare is an organization driven by the vision of turning the NHS Digital First strategy into reality by bringing digital innovation to healthcare providers. Leading healthcare organizations into the digital era by redesigning and developing patient-centric online systems (web & mobile), Capri Healthcare helps significantly reduce the burden on staff as well as the NHS. The company prides itself in offering a range of technology-driven innovative solutions that drive the healthcare industry’s digital agenda. Visit www.caprihealthcare.co.uk .

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release

Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release

Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release

The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release

Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye